{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:51:14Z","timestamp":1793645474831,"version":"4.5.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bbrc.2026.153933","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:05:10Z","timestamp":1778627110000},"page":"153933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A predictive 14-gene signature and FLI1 inhibition overcome tumor-infiltrating lymphocyte dysfunction in triple-negative breast cancer"],"prefix":"10.1016","volume":"823","author":[{"given":"Meng","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanjuan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1086-3718","authenticated-orcid":false,"given":"Hongwei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Ao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaochang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.153933_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2026.153933_bib2","article-title":"Projected global rise in breast cancer incidence and mortality by 2050","author":"Devi","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2026.153933_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41523-024-00679-7","article-title":"Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC","volume":"10","author":"Im","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.bbrc.2026.153933_bib4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2026.153933_bib5","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2026.153933_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000848","article-title":"Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up","volume":"8","author":"van den Berg","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbrc.2026.153933_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008640","article-title":"Biomarkers for response to TIL therapy: a comprehensive review","volume":"12","author":"Albarran Fernandez","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbrc.2026.153933_bib8","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbrc.2026.153933_bib9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.5455\/aim.2018.26.240-244","article-title":"Isolation, characterization and proliferation of cancer cells from breast cancer patients","volume":"26","author":"Widowati","year":"2018","journal-title":"Acta Inf. Med."},{"key":"10.1016\/j.bbrc.2026.153933_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.bbrc.2026.153933_bib11","first-page":"773","article-title":"Advances in tumour-infiltrating lymphocytes for triple-negative breast cancer management","volume":"15","author":"Gorensek","year":"2023","journal-title":"Breast Cancer"},{"key":"10.1016\/j.bbrc.2026.153933_bib12","article-title":"The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.153933_bib13","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2026.153933_bib14","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2026.153933_bib15","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1158\/1078-0432.CCR-21-4499","article-title":"Neoantigen identification and response to adoptive cell transfer in Anti-PD-1 naive and experienced patients with metastatic melanoma","volume":"28","author":"Levi","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"8_Suppl_1","key":"10.1016\/j.bbrc.2026.153933_bib16","article-title":"Targeting fli1 improves antitumor response of CD8 T cells by promoting their activation and limiting exhaustion","volume":"85","author":"Alimohammadi","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.153933_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143950","article-title":"The druggable transcription factor Fli-1 regulates T cell immunity and tolerance in graft-versus-host disease","volume":"132","author":"Schutt","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2026.153933_bib18","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1200\/JCO.24.00020","article-title":"Open-label, multicenter, phase I\/II, first-in-human trial of TK216: a first-generation EWS::FLI1 fusion protein antagonist in ewing sarcoma","volume":"42","author":"Meyers","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.153933_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/genes14101916","article-title":"The small-molecule E26-Transformation-Specific inhibitor TK216 attenuates the oncogenic properties of pediatric leukemia","volume":"14","author":"Sharma","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.bbrc.2026.153933_bib20","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.chembiol.2022.06.002","article-title":"TK216 targets microtubules in Ewing sarcoma cells","volume":"29","author":"Povedano","year":"2022","journal-title":"Cell Chem. Biol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26006972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26006972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T13:06:22Z","timestamp":1781615182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26006972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":20,"alternative-id":["S0006291X26006972"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153933","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A predictive 14-gene signature and FLI1 inhibition overcome tumor-infiltrating lymphocyte dysfunction in triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.153933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153933"}}